OKYO

OKYO Pharma Limited NASDAQ Listed May 17, 2022

Healthcare ·Biotechnology ·GB · okyopharma.com

$1.67

+7.74% vs $1.55

Mkt Cap $64.1M

52w Low $1.34 17.7% of range 52w High $3.20

50d MA $1.56 200d MA $1.78

P/E (TTM) —

EV/EBITDA —

P/B —

Debt/Equity 0.0x

ROE —

P/FCF -36.4x

RSI (14) 64.70

ATR (14) $0.08

Beta -0.12

50d MA $1.56

200d MA $1.78

Avg Volume 95.7K

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

SIC Code

2836

CIK (SEC)

1849296

Phone

44 20 7495 2379

55 Park Lane · London, X0 W1K 1NA · GB

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Jun 3, 2026	AMC	-0.08	-0.04	+49.8%	1.66	+1.8%	+1.2%	-3.6%	-1.9%	-3.1%	-3.2%	—
Jan 30, 2026	AMC	-0.07	-0.01	+85.7%	2.05	-1.5%	+2.0%	+0.5%	-6.7%	-3.1%	+1.1%	—
Jan 29, 2025	AMC	—	-0.08	—	1.07	-1.9%	+2.8%	-3.6%	+0.0%	+6.6%	+1.8%	—
May 13, 2024	AMC	—	-0.30	—	1.48	-1.4%	+2.0%	-1.3%	+4.0%	-1.9%	-2.0%	—
Oct 1, 2023	AMC	—	-0.00	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	-0.00	—	1.68	+3.0%	-3.0%	-12.3%	-0.7%	-9.1%	+6.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Sep 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.25	$2.29	+1.8%	-2.2%	-4.1%	+5.2%	-1.8%	-8.3%
May 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.36	$1.33	-2.2%	+8.8%	+0.7%	-1.3%	+0.7%	-2.0%
May 5	HC Wainwright& Co.	Maintains	Buy → Buy	—	$1.36	$1.33	-2.2%	+8.8%	+0.7%	-1.3%	+0.7%	-2.0%
Feb 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.10	$1.07	-2.7%	-0.9%	-0.9%	+0.9%	+2.8%	-3.6%
Feb 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.07	$1.08	+0.9%	+2.8%	-0.9%	-0.9%	+0.9%	+2.8%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.12	$1.11	-0.9%	-1.8%	-0.9%	+0.0%	-1.8%	+2.8%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.23	$1.19	-3.3%	-10.6%	+14.5%	-9.5%	-1.8%	+4.5%
Oct 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.02	$1.05	+2.9%	+2.9%	-3.8%	+1.0%	-3.9%	+5.1%
Aug 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.95	$0.94	-0.5%	+14.7%	+0.0%	+22.0%	-9.8%	-4.2%
Jul 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.47	$1.53	+4.1%	+8.2%	+0.0%	-1.3%	+1.9%	-0.6%
Jul 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.17	$1.28	+9.4%	+25.6%	+8.2%	+0.0%	-1.3%	+1.9%
Mar 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.76	$1.76	+0.0%	-12.5%	-5.2%	-1.4%	+4.2%	-0.7%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.86	$1.85	-0.5%	+1.6%	-6.3%	-4.0%	-0.6%	+2.4%
Dec 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.73	$1.80	+4.0%	+0.0%	-1.7%	+0.0%	-1.8%	-1.2%

Institutional (13F) — Top 0 All ↗

No 13F holders found.

Mutual Funds / ETFs (N-PORT) — Top 1 All ↗

#	Fund	Shares	Value	Period
1	Fidelity Nasdaq Composite Index Fund	12,090	$21K	Feb 2026

Data updated apr 26, 2026 5:14pm · Source: financialmodelingprep.com